-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
AT-9010 triethylamine
Category | SARS-CoV |
CAS | 2648089-95-4 |
Description | The active triphosphate metabolite AT-9010 can inhibit SARS-CoV-2 replication. |
Product Information
Synonyms | UNII-IR49Q7E87C triethylamine |
IUPAC Name | [[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate,triethylamine |
Molecular Weight | 943.96 |
Molecular Formula | C35H77FN9O13P3 |
Canonical SMILES | CCN(CC)CC.CC1(C(C(OC1N2C=NC3C2=NC(=N)NC3=O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)F |
InChI | InChI=1S/C11H17FN5O13P3.C6H15N/c1-11(12)6(18)4(2-27-32(23,24)30-33(25,26)29-31(20,21)22)28-9(11)17-3-14-5-7(17)15-10(13)16-8(5)19;1-4-7(5-2)6-3/h3-6,9,18H,2H2,1H3,(H,23,24)(H,25,26)(H2,13,16,19)(H2,20,21,22);4-6H2,1-3H3/t4-,5?,6-,9-,11-;/m1./s1 |
InChIKey | IZZBJQQXPMZLRV-VGJFTDQKSA-N |
Purity | ≥98% (HPLC) |
Solubility | In vitro: 10 mM in DMSO |
Appearance | Solid powder |
Storage | Store at -20°C |
In Vitro | Substantial levels of the active triphosphate metabolite AT-9010 are formed in normal human bronchial and nasal epithelial cells incubated with 10 µM AT-511 (698 µM and 236 µM, respectively), with a half-life of at least 38 hours. |
In Vivo | AT-9010-triethylamine is used as a type of inhibitor of SARS-CoV type 2. |
Target | NiRAN |